DUBLIN, Ohio--(BUSINESS WIRE)--Macrophage Therapeutics, a newly created business unit of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), hosted a conference where data was presented using Manocept™ platform compound, tilmanocept, that was generated by independent academic collaborators with expertise in the HIV/AIDS, cancer, tuberculosis (TB), rheumatoid arthritis and cardiovascular disease therapeutic areas. The technical presentations highlighted tilmanocept’s ability to target activated macrophages implicated in pathology. Specifically data were presented in:
1. Kaposi’s Sarcoma cells from human tumor extracts that contain tumor associated macrophages (TAM’s) and are often infected with HIV. Data demonstrated that a generic anticancer agent that has no direct activity vs. HIV, conjugated to tilmanocept killed the CD-206 positive TAM’s.
Help employers find you! Check out all the jobs and post your resume.
1. Kaposi’s Sarcoma cells from human tumor extracts that contain tumor associated macrophages (TAM’s) and are often infected with HIV. Data demonstrated that a generic anticancer agent that has no direct activity vs. HIV, conjugated to tilmanocept killed the CD-206 positive TAM’s.
Help employers find you! Check out all the jobs and post your resume.
